PhilArt – PolyPhil 1 x 2 ml is a professional polynucleotide skin-rejuvenation injectable developed for practitioners seeking regenerative treatment options that focus on skin quality rather than volume replacement. The formulation contains purified polynucleotides designed to support hydration, improve the appearance of skin texture, and contribute to overall dermal revitalisation.
Used by qualified medical professionals, PhilArt is frequently incorporated into aesthetic treatment plans for patients presenting with signs of skin ageing, reduced elasticity, or diminished skin quality. As a non-volumising regenerative injectable, it may be selected when the treatment objective is skin conditioning and tissue support rather than contour enhancement.
Pricing is available to registered aesthetic professionals only.
Sign in to view pricesPhilArt® (also known in some markets as PolyPhil 1 x 2 ml) is a polynucleotide-based injectable medical-aesthetic device designed for tissue revitalisation and skin quality improvement. The product contains highly purified polynucleotides (PN), biomolecules derived through controlled purification processes and intended to support the physiological environment of the skin. Polynucleotides have been studied for their ability to promote hydration, support fibroblast activity, and contribute to extracellular matrix maintenance through indirect biological mechanisms.
PhilArt is commonly used within aesthetic medicine protocols targeting skin quality concerns associated with ageing, environmental stress, and reduced dermal vitality. Unlike volumising dermal fillers, PhilArt is generally positioned as a regenerative injectable rather than a product intended primarily for structural augmentation.
The product is manufactured by Croma-Pharma and is supplied in a sterile injectable format for professional use only.
PhilArt belongs to the growing category of regenerative polynucleotide injectables. Clinically, it is often compared with products such as Nucleofill® and Plinest®, which also utilise purified polynucleotides to support tissue quality and skin revitalisation.
Compared with traditional hyaluronic acid skin boosters, PhilArt relies primarily on polynucleotide technology rather than exogenous hyaluronic acid. While both categories aim to improve skin quality, hydration, and overall appearance, their mechanisms differ. Hyaluronic acid skin boosters focus on hydration and dermal support, whereas polynucleotides are intended to provide a favourable biological environment that may support tissue regeneration processes.
PhilArt is not classified as a volumising filler and should not be considered a direct substitute for structural dermal fillers used for facial contouring or volume restoration.
This comparison is provided for clinical orientation only and does not imply interchangeability.
Publicly available manufacturer information indicates that PhilArt may be used for skin revitalisation and tissue-quality improvement in areas including:
Specific treatment areas may vary according to local regulatory approvals and practitioner assessment.
The following information should be verified against the latest manufacturer Instructions for Use (IFU).
Some practitioners apply specific polynucleotide treatment protocols; however, these methods are not included in the manufacturer’s official IFU and should not be considered manufacturer guidance.
Based on publicly available manufacturer and distributor information:
Not provided by manufacturer (PhilArt is not marketed as a hyaluronic acid filler).
Not provided by manufacturer / no lidocaine content publicly specified.
The duration of clinical effects is influenced by patient characteristics, treatment objectives, anatomical area, and practitioner protocol. A specific longevity claim is not provided by manufacturer within publicly available documentation reviewed.
As with other injectable medical-aesthetic products, treatment should be performed only by appropriately trained healthcare professionals.
Contraindications and precautions may include:
Where available, practitioners should always consult the current manufacturer IFU before administration.
If local regulatory information differs, practitioners should rely on the latest manufacturer documentation supplied with the product.
PhilArt is a polynucleotide-based injectable medical-aesthetic device intended for skin revitalisation and tissue-quality improvement. It contains purified polynucleotides and is designed to support the physiological environment of the skin. Unlike traditional volumising fillers, its primary purpose is regenerative skin support rather than contour enhancement.
Polynucleotides are believed to contribute to tissue support through hydration-related effects and by helping create conditions favourable for fibroblast activity and extracellular matrix maintenance. Current literature suggests that polynucleotide-based treatments may contribute to improvements in skin quality and overall tissue condition when administered by qualified practitioners.
PhilArt is generally classified as a regenerative polynucleotide injectable rather than a traditional volumising dermal filler. While both product categories are injectable aesthetic treatments, dermal fillers are primarily used to restore volume or contour, whereas PhilArt is used for skin quality and tissue revitalisation objectives.
Publicly available manufacturer documentation reviewed for this product does not provide a specific longevity claim. Treatment outcomes and duration can vary according to treatment area, patient factors, practitioner protocol, and maintenance schedules. Practitioners should rely on current manufacturer guidance and clinical judgement when discussing expectations with patients.
PhilArt and Nucleofill are both polynucleotide-based injectable products used within regenerative aesthetic medicine. Both are intended to support skin quality and tissue revitalisation rather than provide substantial volumisation. Differences may exist in formulation characteristics, treatment protocols, approved indications, and manufacturer guidance. Product selection should be based on clinical assessment and official documentation.
Let’s talk on WhatsApp